Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 27 Sep 2018 Status changed from active, no longer recruiting to completed.
- 23 Mar 2018 Planned End Date changed from 30 Jun 2018 to 27 Sep 2018.
- 23 Mar 2018 Planned primary completion date changed from 30 Jun 2018 to 27 Sep 2018.